Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Researchers at University of Pittsburgh release new data on angiogenesis
July 7th, 2009
"Endostatin represents the most studied endogenous anti-angiogenesis peptide that has been found to inhibit angiogenesis and exhibit broad-spectrum antitumor activity in animal models," scientists writing in the journal Expert Opinion on Biological Therapy report. "Clinical trials evaluating endostatin alone or in combination with other currently used strategies for the treatment of solid tumors has generated debatable efficacy results, albeit with low toxicity, immunogenicity and resistance. We delineate the current knowledge regarding endostatin's mechanism of action during carcinogenesis, spotlight already reported and ongoing research concerning its clinical...
Source: Cancer Weekly (2009-07-07)
|
